Home Applications 211371 Application 211371
Type NDA
Sponsor SAGE THERAP Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 ZULRESSO BREXANOLONE SOLUTION;INTRAVENOUS 100MG/20ML (5MG/ML) Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 44 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N211371-001 ZULRESSO BREXANOLONE 100MG/20ML (5MG/ML) SOLUTION / INTRAVENOUS RLD 2019-06-17
Orange Book patents# Current patent rows page 1 of 1 · 8 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N211371-001 10117951 2029-03-13 Drug product 2019-06-27 N211371-001 7635773 2029-03-13 Drug product 2019-06-27 N211371-001 8410077 2029-03-13 Drug product 2019-06-27 N211371-001 9200088 2029-03-13 Drug product 2019-06-27 N211371-001 9750822 2029-03-13 Drug product 2019-06-27 N211371-001 10322139 2033-01-23 Drug product 2019-06-27 N211371-001 10251894 2033-11-27 U-2552 2019-06-27 N211371-001 10940156 2037-03-08 U-2552 2021-04-07
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 44 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-10-28 04:53 UTC 2022-10 N211371-001 ZULRESSO 100MG/20ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2019-06-17 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N211371-001 ZULRESSO 100MG/20ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2019-06-17 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N211371-001 ZULRESSO 100MG/20ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2019-06-17 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N211371-001 ZULRESSO 100MG/20ML (5MG/ML) SOLUTION / INTRAVENOUS RLD 2019-06-17 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 9 · 345 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-10-15 13:18:30 2026-09 N211371-001 10117951 2029-03-13 Drug product 2019-06-27 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211371-001 7635773 2029-03-13 Drug product 2019-06-27 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211371-001 8410077 2029-03-13 Drug product 2019-06-27 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211371-001 9200088 2029-03-13 Drug product 2019-06-27 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211371-001 9750822 2029-03-13 Drug product 2019-06-27 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211371-001 10322139 2033-01-23 Drug product 2019-06-27 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211371-001 10251894 2033-11-27 U-2552 2019-06-27 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211371-001 10940156 2037-03-08 U-2552 2021-04-07 c2088c7a36db…2026-09-14 22:38:34 2026-08 N211371-001 10117951 2029-03-13 Drug product 2019-06-27 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211371-001 7635773 2029-03-13 Drug product 2019-06-27 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211371-001 8410077 2029-03-13 Drug product 2019-06-27 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211371-001 9200088 2029-03-13 Drug product 2019-06-27 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211371-001 9750822 2029-03-13 Drug product 2019-06-27 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211371-001 10322139 2033-01-23 Drug product 2019-06-27 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211371-001 10251894 2033-11-27 U-2552 2019-06-27 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211371-001 10940156 2037-03-08 U-2552 2021-04-07 84e616aacf4f…2026-08-18 06:07:40 2026-07 N211371-001 10117951 2029-03-13 Drug product 2019-06-27 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211371-001 7635773 2029-03-13 Drug product 2019-06-27 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211371-001 8410077 2029-03-13 Drug product 2019-06-27 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211371-001 9200088 2029-03-13 Drug product 2019-06-27 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211371-001 9750822 2029-03-13 Drug product 2019-06-27 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211371-001 10322139 2033-01-23 Drug product 2019-06-27 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211371-001 10251894 2033-11-27 U-2552 2019-06-27 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211371-001 10940156 2037-03-08 U-2552 2021-04-07 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N211371-001 10117951 2029-03-13 Drug product 2019-06-27 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211371-001 7635773 2029-03-13 Drug product 2019-06-27 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211371-001 8410077 2029-03-13 Drug product 2019-06-27 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211371-001 9200088 2029-03-13 Drug product 2019-06-27 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211371-001 9750822 2029-03-13 Drug product 2019-06-27 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211371-001 10322139 2033-01-23 Drug product 2019-06-27 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211371-001 10251894 2033-11-27 U-2552 2019-06-27 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211371-001 10940156 2037-03-08 U-2552 2021-04-07 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N211371-001 10117951 2029-03-13 Drug product 2019-06-27 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N211371-001 7635773 2029-03-13 Drug product 2019-06-27 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N211371-001 8410077 2029-03-13 Drug product 2019-06-27 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N211371-001 9200088 2029-03-13 Drug product 2019-06-27 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N211371-001 9750822 2029-03-13 Drug product 2019-06-27 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N211371-001 10322139 2033-01-23 Drug product 2019-06-27 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N211371-001 10251894 2033-11-27 U-2552 2019-06-27 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N211371-001 10940156 2037-03-08 U-2552 2021-04-07 31067a03dcf5…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 2 · 60 observed states.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 5 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 72152-547 Zulresso brexanolone Sage Therapeutics, Inc. NDA Current 72152-547 Zulresso brexanolone Sage Therapeutics, Inc. NDA Current 72152-547 Zulresso brexanolone Sage Therapeutics, Inc. NDA Current 72152-547 Zulresso brexanolone Sage Therapeutics, Inc. NDA Current 72152-547 Zulresso brexanolone Sage Therapeutics, Inc. NDA Current